Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus SUMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus SUMYCIN.
ACTICLATE CAP vs SUMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic